Rapport Therapeutics Inc., a clinical-stage biotechnology company, announced that it will present new data from its Phase 2a trial of RAP-219 in focal onset seizures at the upcoming 2025 American Epilepsy Society $(AES)$ Annual Meeting, scheduled for December 5-9, 2025, in Atlanta. The presentations will include analyses of RAP-219's effect during the first month of treatment, consistency of efficacy over the treatment period, effectiveness across varying baseline disease severities, and impact on seizure severity. Both topline efficacy and safety data, as well as additional exploratory analyses, will be shared during poster sessions and a dedicated Scientific Exhibit Room at the meeting. The results have not yet been presented and will be made available during the AES conference.